MLTX logo

MoonLake Immunotherapeutics (MLTX) EBITDA

Annual EBITDA:

-$141.71M-$87.60M(-161.89%)
December 31, 2024

Summary

  • As of today, MLTX annual EBITDA is -$141.71 million, with the most recent change of -$87.60 million (-161.89%) on December 31, 2024.
  • During the last 3 years, MLTX annual EBITDA has fallen by -$88.13 million (-164.52%).
  • MLTX annual EBITDA is now -133837.90% below its all-time high of -$105.80 thousand, reached on December 1, 2020.

Performance

1-Year Change

-161.89%

3-Year Change

-164.52%

5-Year Change

-133837.9%

15-Year Change

-133837.9%

MLTX EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Percentile

12.6%
MLTX annual EBITDA is higher than 12.6% of companies in Healthcare sector

Range

All-Time High

-$105.80K
MLTX annual EBITDA is currently >-9900.00% below its historical high of -$105.80 thousand

3-Year Low

-$141.71M
MLTX annual EBITDA is currently at its 3-year low

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2024
MLTX previous annual earnings announcement was published on Dec 31, 2024

Next Annual Earnings Report Date

N/A
MLTX next annual earnings announcement has not yet been scheduled

OtherMLTXincome statement metrics

Annual Revenue

$0.00
MLTX annual revenue is $0.00

Annual Net Income

-$121.24M
MLTX annual net profit is -$121.24 million

Annual EBIT

-$143.09M
MLTX annual earnings before interest & taxes is -$143.09 million

Annual EPS

-$1.89
MLTX annual earnings per share is -$1.89

Quarterly EBITDA:

-$59.96M-$12.85M(-27.28%)
June 30, 2025

Summary

  • As of today, MLTX quarterly EBITDA is -$59.96 million, with the most recent change of -$12.85 million (-27.28%) on June 30, 2025.
  • Over the past year, MLTX quarterly EBITDA has dropped by -$29.41 million (-96.25%).

Performance

3-Month Change

-27.28%

1-Year Change

-96.25%

3-Year Change

-239.65%

5-Year Change

-100%

MLTX Quarterly EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Percentile

6.38%
MLTX quarterly EBITDA is higher than 6.38% of companies in Healthcare sector

Range

All-Time High

$0.00
MLTX quarterly EBITDA is currently >-9900.00% below its historical high of $0.00

3-Year Low

-$59.96M
MLTX quarterly EBITDA is currently at its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Jun 30, 2025
MLTX previous earnings announcement was published on Jun 30, 2025

Next Quarterly Earnings Report Date

Nov 6, 2025
MLTX next earnings announcement is scheduled for Nov 6, 2025

OtherMLTXincome statement metrics

Quarterly Revenue

$0.00
MLTX quarterly revenue is $0.00

Quarterly Net Income

-$56.05M
MLTX quarterly net profit is -$56.05 million

Quarterly EBIT

-$60.70M
MLTX quarterly earnings before interest & taxes is -$60.70 million

Quarterly EPS

-$0.87
MLTX quarterly earnings per share is -$0.87

TTM EBITDA:

-$198.42M-$29.41M(-17.40%)
June 30, 2025

Summary

  • As of today, MLTX TTM EBITDA is -$198.42 million, with the most recent change of -$29.41 million (-17.40%) on June 30, 2025.
  • Over the past year, MLTX TTM EBITDA has dropped by -$120.07 million (-153.26%).

Performance

3-Month Change

-17.4%

1-Year Change

-153.26%

3-Year Change

-266.55%

5-Year Change

-100%

MLTX TTM EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Percentile

7.71%
MLTX TTM EBITDA is higher than 7.71% of companies in Healthcare sector

Range

All-Time High

$0.00
MLTX TTM EBITDA is currently >-9900.00% below its historical high of $0.00

3-Year Low

-$198.42M
MLTX TTM EBITDA is currently at its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Jun 30, 2025
MLTX previous earnings announcement was published on Jun 30, 2025

Next Quarterly Earnings Report Date

Nov 6, 2025
MLTX next earnings announcement is scheduled for Nov 6, 2025

OtherMLTXincome statement metrics

TTM Revenue

$0.00
MLTX TTM revenue is $0.00

TTM Net Income

-$179.12M
MLTX TTM net profit is -$179.12 million

TTM EBIT

-$200.88M
MLTX TTM earnings before interest & taxes is -$200.88 million

TTM EPS

-$2.79
MLTX TTM earnings per share is -$2.79

EBITDA Formula

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

Annual EBITDA

-$141.71M
MLTX annual EBITDA is -$141.71 million

Annual Net Income

-$121.24M
MLTX annual net profit is -$121.24 million

Annual Interest Expense

$0.00
MLTX annual interest expense is $0.00

Annual Income Tax

$282.20K
MLTX annual income tax is $282.20 thousand

Annual D&A

$1.38M
MLTX annual D&A is $1.38 million

MLTX EBITDA Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1Y1 Year-161.9%-96.3%-153.3%
3Y3 Years-164.5%-239.7%-266.6%
5Y5 Years-10000.0%-100.0%-100.0%

MLTX EBITDA Highs & Lows

PeriodPeriodAnnual vs HighAnnual vs HighAnnual vs LowAnnual vs LowQuarter. vs HighQuarter. vs HighQuarter. vs LowQuarter. vs LowTTM vs HighTTM vs HighTTM vs LowTTM vs Low
3Y3-Year-164.5%at low-363.8%at low-266.7%at low
5Y5-Year>-9999.0%at low>-9999.0%at low>-9999.0%at low
All-TimeAll-Time>-9999.0%at low>-9999.0%at low>-9999.0%at low

MLTX EBITDA History

DateAnnualQuarterlyTTM
Jun 2025
-
-$59.96M(-27.3%)
-$198.42M(-17.4%)
Mar 2025
-
-$47.11M(+2.4%)
-$169.02M(-19.3%)
Dec 2024
-$141.71M(-161.9%)
-$48.28M(-12.1%)
-$141.71M(-30.7%)
Sep 2024
-
-$43.08M(-41.0%)
-$108.45M(-38.4%)
Jun 2024
-
-$30.55M(-54.3%)
-$78.35M(-28.5%)
Mar 2024
-
-$19.80M(-31.8%)
-$60.98M(-12.7%)
Dec 2023
-$54.11M(+16.8%)
-$15.03M(-15.8%)
-$54.11M(+3.0%)
Sep 2023
-
-$12.97M(+1.6%)
-$55.78M(+3.1%)
Jun 2023
-
-$13.18M(-2.0%)
-$57.57M(+7.2%)
Mar 2023
-
-$12.93M(+22.6%)
-$62.04M(+4.6%)
DateAnnualQuarterlyTTM
Dec 2022
-$65.05M(-21.4%)
-$16.69M(-13.0%)
-$65.05M(-3.9%)
Sep 2022
-
-$14.77M(+16.3%)
-$62.63M(-15.7%)
Jun 2022
-
-$17.65M(-10.7%)
-$54.13M(+21.7%)
Mar 2022
-
-$15.94M(-11.7%)
-$69.16M(-29.7%)
Dec 2021
-$53.57M(>-9900.0%)
-$14.27M(-127.8%)
-$53.32M(-36.2%)
Sep 2021
-
-$6.26M(+80.8%)
-$39.14M(-19.1%)
Jun 2021
-
-$32.68M(>-9900.0%)
-$32.88M(>-9900.0%)
Mar 2021
-
-$94.10K(+6.6%)
-$194.90K(-93.4%)
Dec 2020
-$105.80K
-$100.80K(>-9900.0%)
-$100.80K(>-9900.0%)
Sep 2020
-
$0.00
$0.00

FAQ

  • What is MoonLake Immunotherapeutics annual EBITDA?
  • What is the all-time high annual EBITDA for MoonLake Immunotherapeutics?
  • What is MoonLake Immunotherapeutics annual EBITDA year-on-year change?
  • What is MoonLake Immunotherapeutics quarterly EBITDA?
  • What is the all-time high quarterly EBITDA for MoonLake Immunotherapeutics?
  • What is MoonLake Immunotherapeutics quarterly EBITDA year-on-year change?
  • What is MoonLake Immunotherapeutics TTM EBITDA?
  • What is the all-time high TTM EBITDA for MoonLake Immunotherapeutics?
  • What is MoonLake Immunotherapeutics TTM EBITDA year-on-year change?

What is MoonLake Immunotherapeutics annual EBITDA?

The current annual EBITDA of MLTX is -$141.71M

What is the all-time high annual EBITDA for MoonLake Immunotherapeutics?

MoonLake Immunotherapeutics all-time high annual EBITDA is -$105.80K

What is MoonLake Immunotherapeutics annual EBITDA year-on-year change?

Over the past year, MLTX annual EBITDA has changed by -$87.60M (-161.89%)

What is MoonLake Immunotherapeutics quarterly EBITDA?

The current quarterly EBITDA of MLTX is -$59.96M

What is the all-time high quarterly EBITDA for MoonLake Immunotherapeutics?

MoonLake Immunotherapeutics all-time high quarterly EBITDA is $0.00

What is MoonLake Immunotherapeutics quarterly EBITDA year-on-year change?

Over the past year, MLTX quarterly EBITDA has changed by -$29.41M (-96.25%)

What is MoonLake Immunotherapeutics TTM EBITDA?

The current TTM EBITDA of MLTX is -$198.42M

What is the all-time high TTM EBITDA for MoonLake Immunotherapeutics?

MoonLake Immunotherapeutics all-time high TTM EBITDA is $0.00

What is MoonLake Immunotherapeutics TTM EBITDA year-on-year change?

Over the past year, MLTX TTM EBITDA has changed by -$120.07M (-153.26%)
On this page